Genetic Alterations in ERBB2-amplified Breast Carcinomas ,

摘要: Amplification of the ERBB2 oncogene has recently received attention as a target for antibody-based therapies and predictor response to adjuvant chemotherapy. Modification treatment strategies based on status led further interest in genetic alterations that accompany gene amplification or overexpression. In this study, chromosome are associated with were defined by comparative genomic hybridization (CGH). Additionally, fluorescence situ (FISH) was used validate amplification, protein expression detected immunohistochemically. ERBB2-amplified tumors FISH, immunohistochemistry (IHC), CGH had twice many CGH-defined chromosomal (means 11.8, 11.0, 12.7, respectively) nonamplified 6.8, 7.0, 5.6, respectively). positivity correlated total number events. A wide spectrum copy gains losses seen all tumors. An increased 18q 20q found ERBB2-positive Other common aberrations 1q (58%), 8q (52%), (30%), (39%), 13q 3p (33%). high degree concordance observed among three methods 33 primary breast cancers. The concurrence detection between FISH IHC 90%, 82%, 84%. This study shows showing erbB2 overexpression genetically distinct from erbB2-negative These differences may relate mechanisms underlying altered define responsiveness erbB2-directed immunotherapy.